Search | Clinical Trials Finder

Conditions: Giant Cell Arteritis (GCA)
Interventions: Upadacitinib, Corticosteroid (CS), Placebo; Drug · Other
Lead sponsor: AbbVie; Industry
Eligibility: 50 Years and older
Enrollment: 429 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2025
U.S. locations: 53
States / cities: Huntsville, Alabama • Glendale, Arizona • Long Beach, California + 46 more

Conditions: Asthma
Interventions: Dupilumab, Placebo, Oral corticosteroid therapy (prednisone/prednisolone), Inhaled corticosteroid (ICS) therapy, Albuterol/Salbutamol, Levalbuterol/Levosalbutamol; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 12 Years and older
Enrollment: 210 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 8
States / cities: Los Angeles, California • Rolling Hills Estates, California • St Louis, Missouri + 4 more

Conditions: Giant Cell Arteritis (GCA)
Interventions: Secukinumab 300 mg, Placebo, Secukinumab 150 mg; Biological · Other
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 50 Years to 100 Years
Enrollment: 354 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 10
States / cities: Los Angeles, California • Plantation, Florida • Sarasota, Florida + 6 more

Conditions: Rheumatoid Arthritis
Interventions: Prednisolone, dipyridamole, Prednisone, Z102, placebo; Drug · Other
Lead sponsor: Zalicus; Industry
Eligibility: 18 Years and older
Enrollment: 294 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: Toledo, Ohio

Conditions: Acute Lymphocytic Leukemia, Adult Lymphoblastic Lymphoma
Interventions: DNR, VCR, PEG-asp, CTX, Prednisone, Liposomal AraC, MTX, LCV, AraC, Etoposide, Dasatinib, Rituximab, Hydrocortisone; Drug
Lead sponsor: University of California, San Diego; Other
Eligibility: 18 Years to 60 Years
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2022
U.S. locations: 4
States / cities: La Jolla, California • Los Angeles, California • Sacramento, California + 1 more

Conditions: Diffuse Large B-cell Lymphoma (DLBCL), Cardiotoxicity, Lymphoma
Interventions: Dexrazoxane, Dexrazoxane placebo, Doxorubicin, Liposomal Doxorubicin, Cyclophosphamide, Vincristine, Prednisone, Rituximab, Polatuzumab Vedotin; Drug
Lead sponsor: Beth Israel Deaconess Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2035
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Prostatic Neoplasms
Interventions: Pembrolizumab, Docetaxel, Prednisone, Placebo, Dexamethasone; Biological · Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 1,030 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 28
States / cities: Mobile, Alabama • Fullerton, California • Los Angeles, California + 24 more

Conditions: Lung Cancer, Lung Metastases
Interventions: Nintedanib, Prednisone, Placebo; Drug · Other
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2024
U.S. locations: 12
States / cities: Boston, Massachusetts • Basking Ridge, New Jersey • Middletown, New Jersey + 9 more

Conditions: Corticosteroid Resistant (CR) Asthmatics
Interventions: AZD7624, prednisone, Placebo; Drug
Lead sponsor: National Jewish Health; Other
Eligibility: 18 Years to 65 Years
Enrollment: 2 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Denver, Colorado

Conditions: Arthritis, Rheumatoid
Interventions: TRU-015, Methylprednisolone, Prednisone; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 222 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2012
U.S. locations: 29
States / cities: Birmingham, Alabama • Paradise Valley, Arizona • Los Angeles, California + 24 more

Conditions: Total Hip Replacement
Interventions: Prednisone, Hydrocortisone, Placebo (for Prednisone); Drug
Lead sponsor: Hospital for Special Surgery, New York; Other
Eligibility: 50 Years to 90 Years
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2014
U.S. locations: 1
States / cities: New York, New York

Conditions: Prostate Cancer
Interventions: Saruparib, Placebo, Abiraterone + Prednisolone/Prednisone, Androgen Deprivation Therapy (ADT); Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 700 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2036
U.S. locations: 45
States / cities: Phoenix, Arizona • Tucson, Arizona • La Jolla, California + 40 more

Conditions: Status Asthmaticus
Interventions: Ipratropium, 0.9% Sodium Chloride, Albuterol, corticosteroids; Drug
Lead sponsor: University Hospitals Cleveland Medical Center; Other
Eligibility: 2 Years to 17 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Prostate Cancer
Interventions: enzastaurin, placebo, docetaxel, prednisone; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 108 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 22
States / cities: Fullerton, California • Los Angeles, California • Northridge, California + 19 more

Conditions: Myasthenia Gravis Generalised
Interventions: mycophenolate mofetil [CellCept], Placebo; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 136 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2007
U.S. locations: 3
States / cities: Sun City, Arizona • Sacramento, California • Upland, Pennsylvania

Conditions: Cellulitis
Interventions: Prednisone, Placebo; Drug
Lead sponsor: Albert Einstein Healthcare Network; Other
Eligibility: 18 Years to 70 Years
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Metastatic Castration-resistant Prostate Cancer
Interventions: DCVAC/PCa, Placebo; Biological
Lead sponsor: SOTIO a.s.; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 1,182 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2020
U.S. locations: 58
States / cities: Mobile, Alabama • Chandler, Arizona • Scottsdale, Arizona + 52 more

Conditions: Anaplastic Large-Cell Lymphoma, Non-Hodgkin Lymphoma, T-Cell Lymphoma
Interventions: brentuximab vedotin, doxorubicin, prednisone, vincristine, cyclophosphamide; Drug
Lead sponsor: Seagen Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 452 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2020
U.S. locations: 32
States / cities: Gilbert, Arizona • Duarte, California • Stanford, California + 24 more

Conditions: ANCA-Associated Vasculitis
Interventions: Avacopan, Prednisone, Cyclophosphamide, Rituximab, Azathioprine; Drug · Biological
Lead sponsor: Amgen; Industry
Eligibility: 12 Years and older
Enrollment: 331 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 41
States / cities: Huntsville, Alabama • Phoenix, Arizona • Los Angeles, California + 35 more

Conditions: Allergic Asthma
Interventions: Omalizumab, Placebo, Asthma therapies; Drug
Lead sponsor: Genentech, Inc.; Industry
Eligibility: 17 Years to 70 Years
Enrollment: 176 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 100
States / cities: Huntsville, Alabama • Little Rock, Arkansas • Bakersfield, California + 87 more

Conditions: Hypereosinophilic Syndrome
Interventions: Mepolizumab 300 mg, Placebo matching mepolizumab, Active OCS capsules (5 mg prednisolone or prednisone), Placebo matching OCS capsules; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 12 Years and older
Enrollment: 108 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 7
States / cities: San Diego, California • New Haven, Connecticut • Rochester, Minnesota + 4 more

Conditions: HIV Infections, AIDS-Associated Nephropathy
Interventions: Prednisone; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years and older
Enrollment: 54 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 1996
U.S. locations: 8
States / cities: Los Angeles, California • San Francisco, California • Torrance, California + 4 more

Conditions: Gout
Interventions: Pegloticase, methotrexate, placebo, folic acid, gout flare prophylaxis regimen, fexofenadine, acetaminophen, methylprednisolone; Biological · Drug · Dietary Supplement
Lead sponsor: Amgen; Industry
Eligibility: 18 Years and older
Enrollment: 152 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 60
States / cities: Birmingham, Alabama • Anchorage, Alaska • Flagstaff, Arizona + 54 more

Conditions: Uveitis
Interventions: Sarilumab, Prednisone, Methotrexate, Folic/folinic acid, Placebo (for Sarilumab); Drug · Other
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years and older
Enrollment: 58 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 5
States / cities: Worcester, Massachusetts • Omaha, Nebraska • Slingerlands, New York + 2 more

Search by objective public record fields.

A Study to Evaluate the Safety and Efficacy of Upadacitinib in Participants With Giant Cell Arteritis

Evaluation of Dupilumab in Patients With Severe Steroid Dependent Asthma

Phase III Study of Efficacy and Safety of Secukinumab Versus Placebo, in Combination With Glucocorticoid Taper Regimen, in Patients With Giant Cell Arteritis (GCA)

A Phase II Trial Comparing Z-102 With Placebo In Patients With Moderate To Severe Rheumatoid Arthritis

Chemotherapy With Liposomal Cytarabine CNS Prophylaxis for Adult Acute Lymphoblastic Leukemia & Lymphoblastic Lymphoma

The CARDIOPROTECT Trial

Study of Pembrolizumab (MK-3475) Plus Docetaxel Versus Placebo Plus Docetaxel in Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-3475-921/KEYNOTE-921)

Study to Evaluate the Efficacy and Safety of Nintedanib (BIBF 1120) + Prednisone Taper in Patients With Radiation Pneumonitis

Effects of p38 Inhibitor AZD7624 in Corticosteroid Resistant Asthma

Study Evaluating 2 Dosing Regimens Of TRU-015 In Rheumatoid Arthritis

Effect of Steroids on Thrombosis (Blood Clot Formation) and Inflammation in Patients Undergoing Hip Surgery

A Study of Metastases Free Survival With Saruparib vs Placebo Added to a Standard RT/ADT in Men With High-risk Prostate Cancer With a BRCA Mutation

Phase I, Placebo-Controlled, Blinded Pilot Study of Ipratropium in Children Admitted to the ICU With Status Asthmaticus

A Phase 2 Study With Enzastaurin Plus Chemotherapy or Placebo Plus Chemotherapy for Prostate Cancer Patients

A Continuation Study to Assess the Effect of CellCept in Patients With Myasthenia Gravis.

Use of a Single Dose of Oral Prednisone in the Treatment of Cellulitis

Phase III Study of DCVAC/PCa Added to Standard Chemotherapy for Men With Metastatic Castration Resistant Prostate Cancer

ECHELON-2: A Comparison of Brentuximab Vedotin and CHP With Standard-of-care CHOP in the Treatment of Patients With CD30-positive Mature T-cell Lymphomas

A Phase 3 Clinical Trial of CCX168 (Avacopan) in Patients With ANCA-Associated Vasculitis

A Study Evaluating the Persistency of Response With or Without Xolair (Omalizumab) After Long-term Therapy

Efficacy and Safety Study of Mepolizumab in Subjects With Severe Hypereosinophilic Syndrome (HES)

A Phase II Randomized, Double-Blind, Placebo-Controlled Trial to Determine the Efficacy of Prednisone Therapy in HIV-Associated Nephropathy (HIVAN)

Study of KRYSTEXXA® (Pegloticase) Plus Methotrexate in Participants With Uncontrolled Gout

Phase II Study to Analyze Sarilumab in Non-Infectious Uveitis